alexa Lidocaine patch 5\% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial.


Journal of Anesthesia & Clinical Research

Author(s): Katz NP, Gammaitoni AR, Davis MW, Dworkin RH Lidoderm Pat

Abstract Share this page

Abstract OBJECTIVE: To assess the effectiveness of the lidocaine patch 5\% (Lidoderm), a targeted peripheral analgesic, in reducing pain intensity/interference with quality of life (QOL) among patients with postherpetic neuralgia (PHN). DESIGN: Open-label, nonrandomized, effectiveness study; up to three patches applied to area of greatest pain for 12 hours per day for 28 days. SETTING: Forty-two centers consisting of large institutional primary care programs and academic centers, including pain centers, neurologists, and pain specialists affiliated with a university. PATIENTS: Patients with PHN (N = 332). OUTCOME MEASURES: Patients completed the Brief Pain Inventory Short Form and global pain assessments at baseline, Days 7 and 14, and study conclusion. Physicians completed global assessments at baseline and study conclusion. RESULTS: The mean time from onset of herpes zoster to treatment was 28 months. Use of the lidocaine patch 5\% was associated with reductions in all mean pain intensity, pain interference with QOL, and composite scores at all time points (P = 0.0001). Overall, 66\% of patients reported improvement in pain intensity, and 74\% reported improved QOL by Day 7; approximately 43\% who did not respond by Day 7 experienced improvement in pain intensity by Day 14. For all measures of pain intensity, relief, and interference with QOL, improvements from baseline were equally significant regardless of time since shingles onset. In all, approximately 60\% of patients reported moderate to complete pain relief at final evaluation. The lidocaine patch 5\% was well tolerated. CONCLUSIONS: Based on results of previous randomized, controlled trials and the current study, designed to gauge response in the clinical practice setting, the lidocaine patch 5\% should be considered a first-line therapy, alone or in combination with other agents, for PHN due to its efficacy, safety, minimal systemic side effects and drug interactions, and ease of administration. Although the lidocaine patch 5\% was equally effective in longstanding PHN, it would appear prudent to begin therapy as early in the course of PHN as possible. This article was published in Pain Med and referenced in Journal of Anesthesia & Clinical Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version